News/ News/ Oncology FDA to quickly review Novartis’ capmatinib in rare lung cancer Richard Staines cancer, capmatinib, Incyte, lung cancer, Merck KGaA, Novartis 0 Comment The FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share X FDA to quickly review Novartis’ capmatinib in rare lung cancer https://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
cancer, capmatinib, Incyte, lung cancer, Merck KGaA, Novartis
0 Comment
